ライフサイエンスコーパス: HLA-mismatched

1 The majority of donor recipient pairs were HLA mismatched (4.6+/-1.2 of the six major HLA antigens)

2 Fifty-two donor/recipient pairs were HLA-mismatched, 41 at HLA-A and -B and 11 at HLA-DR and

3 ithout significant suppression of completely HLA-mismatched, Ag-induced proliferation.

4 g beads containing the corresponding donor's HLA-mismatched Ags.

5 nancies receiving a human leukocyte antigen (HLA)-mismatched allo-HSCT.

6 ; n = 577) as well as to patients undergoing HLA-mismatched allo HCT.

7 Human leukocyte antigen (HLA)-mismatched allogeneic hematopoietic stem cell trans

8 rom those mediating GVL in each of the eight HLA-mismatched and one HLA-matched donor/recipient pairs

9 CT recipients, including 125 cord blood, 125 HLA-mismatched, and 154 HLA-matched HCTs, detection of m

10 d T-replete grafts, 97% received marrow, 95% HLA-mismatched, and 97% received calcineurin-based graft

11 In this phase 1 and 2 trial, we administered HLA-mismatched anti-CD19 CAR-NK cells derived from cord

12 mulator used for priming, but not on control HLA-mismatched APC.

13 merism can be induced in adult recipients of HLA-mismatched bone-marrow transplantation by a non-myel

14 aft survival for 7614 HLA-matched and 81,364 HLA-mismatched cadaveric kidney transplantations reporte

15 rvous system of a child who had undergone an HLA-mismatched cadaveric lung transplant.

16 719 recipients of primary HLA-mismatched cadaveric or living-donor renal allograft

17 olimus effectively mitigate allorejection of HLA-mismatched CAR-T cells in immunocompetent humanized

18 A similar effect was observed among HLA-mismatched cases (28%, 22%, and 19%, respectively).

19 hanisms for this, we compared the ability of HLA-mismatched CB and adult peripheral blood (PB) T cell

20 tologous DC, Mtb-infected autologous DC, and HLA-mismatched CD1+ targets (DC), as well as HLA-mismatc

21 HLA-mismatched CD1+ targets (DC), as well as HLA-mismatched CD1- targets (macrophages).

22 achieve the same degree of HIV inhibition as HLA-mismatched CD8(+) T cells.

23 beta2-microglobulin to evade recognition by HLA-mismatched CD8+ T cells, and then restored NK cell t

24 LA-matched set and relapse (P < .001) in the HLA-mismatched cohort.

25 as primary end point.RESULTSOS was lower in HLA mismatched compared with fully matched transplants (

26 HLA-mismatched cord blood should be considered an accept

27 Simulations using 46 ICPs and 11 fully HLA-mismatched CPs were undertaken using the Australian

28 ing KIR ligand' might not be limited only to HLA mismatched donor-recipient combinations but may be a

29 th year of transplant (P = 0.015), having an HLA-mismatched donor (P < 0.001), and being a male recip

30 e analysis, GF was associated with having an HLA-mismatched donor (P < 0.05) or MUD (P = 0.015) and w

31 sed risk of sclerosis included the use of an HLA-mismatched donor and a major ABO-mismatched donor.

32 nosis of acute leukemia, a transplant from a HLA-mismatched donor and from cord blood, older age, and

33 HLA-mismatched donor bone-marrow transplantation after s

34 Alloanergization of HLA-mismatched donor T cells efficiently and selectively

35 rst transplant between 2010 and 2019 from an HLA-mismatched donor using TCRalphabeta (n = 167) or PTC

36 -reactive T cell repertoire for any specific HLA-mismatched donor-recipient pair.

37 A webtool for PBM-matching of single class I HLA-mismatched donor-recipient pairs was developed.

38 hematopoietic stem-cell transplantation with HLA mismatched donors.

39 HSCT using human leukocyte antigen (HLA)-mismatched donors is historically associated with i

40 HSCs from 2 human lymphocyte antigen (HLA)-mismatched donors were injected individually or sim

41 56), matched unrelated donors (MUDs, 66), or HLA-mismatched donors (38).

42 patients who received transplantations from HLA-mismatched donors (39.5% +/- 10.4%, P <.05) or HLA-m

43 The increased risk associated with URD/HLA-mismatched donors (RR = 3.8) was limited to patients

44 Although HLA-mismatched donors can mount high-avidity CTLs agains

45 sis, a Lansky/Karnofsky score <90 and use of HLA-mismatched donors negatively affected survival.

46 ografts and/or transplants from unrelated or HLA-mismatched donors seem to be predominantly affected.

47 suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protoc

48 ation of WT1-specific T cells generated from HLA-mismatched donors should be performed with appropria

49 Fifty-seven HLA-matched donors, 12 HLA-mismatched donors, and 1 CD3(+)TCR alphabeta/CD19 de

50 ng bone marrow transplants from unrelated or HLA-mismatched donors.

51 utcomes are historically inferior when using HLA-mismatched donors.

52 al and ethnic groups more frequently rely on HLA-mismatched donors.

53 or patients with end-stage renal disease and HLA-mismatched donors.

54 ed EBV-specific CTL to autologous but not to HLA-mismatched EBV+ tumors as early as 24 h after intrav

55 traperitoneally with autologous but not with HLA-mismatched EBV-LCL had significantly improved surviv

56 with grafts that were HLA-matched (n=35) or HLA-mismatched for one (n=201) or two antigens (n=267) (

57 uiescence (operational tolerance) against an HLA-mismatched graft, allowing them to withdraw all immu

58 y in the setting of human leukocyte antigen (HLA)-mismatched grafts where residual host lymphocytes c

59 as opposed to 79% for MUD grafts and 56% for HLA-mismatched grafts (P = 0.03).

60 ymocyte globulin (ATG) use, and unrelated or HLA-mismatched grafts (URD/HLA mismatch).

61 allografts increases the risk of failure of HLA-mismatched grafts during the first year after transp

62 disease, the risk of death was higher in the HLA-mismatched group than in the cord-blood group (hazar

63 associations was lower (hazard ratio in the HLA-mismatched group, 1.28; 95% CI, 0.51 to 3.25; P=0.60

64 azard ratios were lower (hazard ratio in the HLA-mismatched group, 1.36; 95% CI, 0.76 to 2.46; P=0.30

65 in the cord-blood group (hazard ratio in the HLA-mismatched group, 3.01; 95% CI, 1.22 to 7.38; P=0.02

66 n of multiple viruses included cord blood or HLA-mismatched HCT, myeloablative conditioning, and acut

67 es, with a particularly beneficial impact on HLA-mismatched HCT.

68 tide-specific CD8 T cells were isolated from HLA-mismatched healthy donors and subjected to a stringe

69 KIR/HLA mismatched hematopoietic stem cell transplants induc

70 o being applied to permit transplantation of HLA mismatched hematopoietic stem cells to patients with

71 ) transgenic mice and in patients undergoing HLA-mismatched hematopoietic cell transplantation (HCT),

72 titution while limiting alloreactivity after HLA-mismatched hematopoietic stem cell transplantation,

73 developed a single human leukocyte antigen (HLA)-mismatched heterotopic murine heart transplant mode

74 -CD25 immunotoxin following stimulation with HLA-mismatched host LCLs more consistently depleted in v

75 capacity may enable their persistence in an HLA-mismatched host.

76 s in HIV-1 that persist upon transmission to HLA-mismatched hosts may spread in the population as the

77 In HLA-mismatched HSCT, alloreactivity occurs when licensed

78 ic viral infections underwent an allogeneic, HLA-mismatched HSCT.

79 tion, SCID-hu mice were transplanted with an HLA-mismatched human fetal pancreas.

80 s from two patients were cotransplanted with HLA-mismatched human islets into immunodeficient mice.

81 lls) was alloantigen-specific expanded using HLA-mismatched immature, mature monocyte-derived dendrit

82 GVHD had marrow donors who were unrelated or HLA-mismatched in 27/63 cases.

83 gical rejection of Human Leukocyte Antigens (HLA)-mismatched induced pluripotent stem cells (iPSCs) l

84 logy and immunophenotyping, the transplanted HLA-mismatched kidney organoids trigged a robust alloimm

85 After March 1995, 1067 zero HLA-mismatched kidneys that were not phenotypically iden

86 However, the 5-year graft survival rate in HLA-mismatched kidneys without DGF was significantly hig

87 d kidneys, and most recently to sharing zero HLA-mismatched kidneys.

88 cadaver kidneys is justifiable only for zero-HLA-mismatched kidneys.

89 ly higher killing of autologous LCLs than of HLA-mismatched LCLs (mean, 56% vs. 14% at 20:1 ratio).

90 Here we addressed these questions using HLA-mismatched liver allografts to discriminate the live

91 31, p=0.0003) and possibly after one-antigen HLA-mismatched low-cell-dose umbilical-cord-blood transp

92 100(+) HLA-matched melanoma targets, but not HLA-mismatched melanoma or gp100(-) nonmelanoma tumor li

93 ture of the same target cells with activated HLA-mismatched mitogen-activated lymphomononuclear cells

94 ility complex (MHC) human leukocyte antigen (HLA)-mismatched mixed chimerism is a promising approach

95 isotype-matched control antibody were fed to HLA-mismatched monocyte-derived immature DCs.

96 We treated mice with HLA-mismatched mouse cardiac transplant with atorvastati

97 They did not lyse either HLA-mismatched, MYCN-amplified, or matched/nonmatched, n

98 n followed by donor-recipient inhibitory KIR-HLA mismatched NK cells is well tolerated by patients an

99 n-like receptor-human leukocyte antigen (KIR-HLA) mismatched NK cells (median, 29 x 10(6)/kg NK cells

100 Allogeneic, HLA-mismatched off-the-shelf third-party donors may offe

101 bearing both the autologous and either fully HLA-mismatched or genotypically related haplotype-sharin

102 Transplantation using T-cell depletion or HLA-mismatched or umbilical cord donors was also exclude

103 Donors were unrelated, HLA mismatched, or both in 59% of patients.

104 patients, partially human leukocyte antigen (HLA)-mismatched, or HLA-haploidentical, related donor bo

105 In 141 HLA-mismatched pairs, 28% were matched for DPB1.

106 %) in matched and 32% (95% CI, 8% to 52%) in HLA-mismatched patients (P = .57).

107 Bortezomib-treated HLA-mismatched patients experienced rates of NRM, acute

108 aluable patients in group 2, the regimen for HLA-mismatched patients was changed in 1984 to include C

109 With HLA-mismatched peripheral blood mononuclear cell (PBMC)

110 HLA-mismatched placental blood from unrelated donors is

111 y results of transplantation using partially HLA-mismatched placental blood from unrelated donors.

112 HLA-matched family donors are available, but HLA-mismatched procedures are associated with substantia

113 and compared with those against equivalently HLA mismatched recipient:third-party controls.

114 A-matched recipient and the other went to an HLA-mismatched recipient.

115 Four human leukocyte antigen (HLA)-mismatched recipients of living donor kidney transp

116 ed risk of rejection over the first year for HLA-mismatched recipients (0.87, P<0.001).

117 No grades 3 to 4 aGVHD occurred in 11 HLA-mismatched recipients in the 1.5 mg/m(2) group.

118 crochimerism can be achieved without GVHD in HLA-mismatched recipients of combined kidney and hematop

119 llow-up in a phase IIb tolerance protocol in HLA-mismatched recipients of living donor kidney plus fa

120 l value of CREG matching observed in the one-HLA-mismatched recipients of the UNOS (but not the Pitts

121 ) with unrelated or human leukocyte antigen (HLA) mismatched related donor (relative risk [RR] = 4.1)

122 from unrelated and human leukocyte antigen (HLA)-mismatched related donors.

123 allografting using human leukocyte antigen (HLA)-mismatched related donors.

124 new GVHD risk factors and high-risk groups: HLA-mismatched related (haplo) and unrelated (MMUD) dono

125 l-depleted marrow from an unrelated donor or HLA-mismatched related donor, the risk of developing lym

126 -cell-depleted transplants from unrelated or HLA-mismatched related donors from 1982 to 1994.

127 amide (PTCy), which has increased the use of HLA-mismatched related donors to levels comparable to HL

128 HLA-matched alloBMT and increase the use of HLA-mismatched related donors.

129 There were no differences in survival after HLA-mismatched related, HLA-matched unrelated, or mismat

130 Thirty-one patients received marrow from HLA-mismatched relatives who differed by one or more loc

131 d grafts from HLA-matched siblings, 13% from HLA-mismatched relatives, 12% from HLA-matched, and 41%

132 571 unique peripheral blood samples from 348 HLA-mismatched renal transplant recipients and 101 nontr

133 ng cell line HTC 9062 were used to stimulate HLA-mismatched responder cells from 8 individuals.

134 The triple HLA-mismatched SCID-hu model represents a novel in vivo

135 0), suggesting that the allograft of Class I HLA-mismatched seropositive donors is inaccessible to CD

136 high risk of GVHD, infection, or both in an HLA-mismatched setting.

137 -HLA polymorphisms in the unrelated HSCT and HLA-mismatched setting.

138 In 47 recipients of unrelated and HLA-mismatched stem cells, mortality at transplantation

139 This was done sequentially in two sets of HLA-mismatched surgeries, with patients 1 and 2 receivin

140 elp widen applicability if the challenges of HLA-mismatched T-cell therapy can be addressed.

141 argets sharing HLA class I antigens, but not HLA mismatched targets.

142 cific T cells can have cross-reactivity with HLA-mismatched targets in vitro.

143 ll receptors (TCRs) isolated from allogeneic HLA-mismatched TCR repertoires has, however, been impede

144 us EBV+ tumors, one autologous and the other HLA mismatched to the EBV-specific CTL donor, had regres

145 human histocompatibility leukocyte antigen (HLA)-mismatched, transformed, B lymphocyte cell lines (L

146 When considering HLA-mismatched transplantation for Hodgkin or non-Hodgki

147 or treatment of patients with leukemia after HLA-mismatched transplantation.

148 sulting in particularly high mortality after HLA-mismatched transplantation.

149 ficial for control of GVHD in T-cell-replete HLA-mismatched transplantation.

150 evance for predicting HSCT outcome, even for HLA mismatched transplants.

151 HLA-mismatched transplants with either in vitro depletio

152 transplants, as compared with 37 percent for HLA-mismatched transplants.

153 tively, for HLA-matched transplants than for HLA-mismatched transplants.

154 In a human skin-xenograft model, HLA-mismatched Tregs are swiftly eliminated by recipient

155 s' restricting HLA allele but not in EBV- or HLA-mismatched tumors.

156 ecipients of 0 to 3 human leukocyte antigen (HLA)-mismatched UCB and HLA-A, B, DRB1-matched BM was pe

157 tched unrelated CB (UCB) (57%; P = .031) and HLA-mismatched UD (41%; P = .007).

158 ng us to classify 1,629/2,391 (68.1%) of the HLA-mismatched UD-HCT as PBM-matched or PBM-mismatched.

159 inform mortality risks after single class I HLA-mismatched UD-HCT, suggesting that prospective consi

160 -B, and -C disparities after single class I HLA-mismatched UD-HCT.

161 been observed in leukemia patients receiving HLA-mismatched umbilical cord (UCB) transplants.

162 were higher after transplants of two-antigen HLA-mismatched umbilical cord blood (relative risk 2.31,

163 e use of HLA-matched and one- or two-antigen HLA-mismatched umbilical cord blood in children with acu

164 tal-body irradiation and then transplants of HLA-mismatched umbilical-cord blood.

165 Relapse rates were lower after two-antigen HLA-mismatched umbilical-cord-blood transplants (0.54, p

166 or cord blood transplantation from partially HLA-mismatched units can cure many children with leukemi

167 ling (n = 1), HLA-matched unrelated (n = 9), HLA-mismatched unrelated (n = 3), and HLA haploidentical

168 an HLA-matched unrelated donor (344), or an HLA-mismatched unrelated donor (98).

169 HLA-mismatched unrelated donor (MMUD) hematopoietic stem

170 tigated its impact in patients receiving 7/8 HLA-mismatched unrelated donor (MMUD) or 8/8 HLA-matched

171 of any age with a haploidentical relative or HLA-mismatched unrelated donor and patients age 13 years

172 Life-threatening risks associated with HLA-mismatched unrelated donor hematopoietic cell transp

173 Outcome after HLA-mismatched unrelated donor transplantation is influe

174 s) undergoing transplantation with partially HLA-mismatched unrelated donor umbilical cord blood were

175 er than 25 x 10(9)/L before transplantation, HLA-mismatched unrelated donor, ASXL1 mutation, and non-

176 bility after receipt of a transplant from an HLA-mismatched unrelated donor.

177 ing peripheral blood stem cells (PBSCs) from HLA-mismatched unrelated donors (MMUDs) by reducing the

178 ymorphisms (SNPs) in 2628 patients and their HLA-mismatched unrelated donors to determine whether SNP

179 elatives, 12% from HLA-matched, and 41% from HLA-mismatched unrelated donors.

180 d CML CFU-GM comparably to effectors from 14 HLA-mismatched unrelated individuals (mean inhibition 42

181 hypothesis that removal of CD4 cells from an HLA-mismatched unrelated marrow graft would substantiall

182 plus placebo, and a single-arm stratum (7/8-HLA-mismatched URD) comparing CNI/MTX plus abatacept ver

183 Overall graft failure risk was higher among HLA-mismatched versus HLA-matched transplants (adjusted

184 cate that the adoptive transfer of partially HLA-mismatched virus-specific CTL is safe despite in vit

185 transplants where donors and recipients are HLA mismatched, we distinguish between donor liver-deriv